Alpha Healthcare Acquisition Corp. III Announces Non-Binding Letter Of Intent To Acquire A Commercial Stage Regenerative Medicine Company Conditioned Upon Closing Of Carmell Business Combination
Portfolio Pulse from Happy Mohamed
Alpha Healthcare Acquisition Corp. III (NASDAQ:ALPA) announced a non-binding letter of intent to acquire a commercial stage regenerative medicine company, conditioned upon the closing of ALPA's initial business combination with Carmell Therapeutics Corporation. The target company has approximately $50 million in unaudited TTM net revenue and $5 million in unaudited TTM EBITDA.
June 27, 2023 | 12:25 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ALPA announces intent to acquire a regenerative medicine company upon closing of business combination with Carmell Therapeutics. The target company has $50 million in TTM net revenue and $5 million in TTM EBITDA.
The acquisition of a commercial stage regenerative medicine company with strong financials ($50 million in TTM net revenue and $5 million in TTM EBITDA) will likely have a positive impact on ALPA's stock price in the short term, as it expands the company's portfolio and increases its market presence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100